Holen Sie sich die Stockscreener-App
5.20
0.38%
-0.02
Vorhandelsmarkt:
5.20
Schlusskurs vom Vortag:
$5.22
Offen:
$5.31
24-Stunden-Volumen:
714.45K
Relative Volume:
0.75
Marktkapitalisierung:
$371.29M
Einnahmen:
$14.20M
Nettoeinkommen (Verlust:
$-49.59M
KGV:
-6.1728
EPS:
-0.8424
Netto-Cashflow:
$-35.25M
1W Leistung:
+4.00%
1M Leistung:
+14.29%
6M Leistung:
+145.28%
1J Leistung:
+448.81%
1-Tages-Spanne:
$5.11
$5.40
1-Wochen-Bereich:
$4.66
$5.40
52-Wochen-Spanne:
$0.9011
$5.81
Opus Genetics Inc Stock (IRD) Company Profile
Firmenname
Opus Genetics Inc
Sektor
Branche
Telefon
248-681-9815
Adresse
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
5.20 | 371.29M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-03-16 | Eingeleitet | Oppenheimer | Outperform |
| 2026-01-20 | Eingeleitet | BTIG Research | Buy |
| 2025-12-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-11-25 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-29 | Eingeleitet | Wedbush | Outperform |
| 2025-10-16 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-04-11 | Eingeleitet | Craig Hallum | Buy |
| 2024-11-13 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Opus Genetics Inc Aktie (IRD) Neueste Nachrichten
Here is Why Opus Genetics (IRD) is One of the Best Performing NASDAQ Stocks - Yahoo Finance
Citizens reiterates Opus Genetics stock rating on FDA program acceptance - Investing.com UK
Citizens reiterates Opus Genetics stock rating on FDA program acceptance By Investing.com - Investing.com Australia
Opus Genetics’ LCA5 gene therapy accepted into FDA program - Investing.com
FDA rare-disease program takes in Opus therapy for childhood blindness - Stock Titan
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program - GlobeNewswire
Citizens reiterates Opus Genetics stock rating on gene therapy data By Investing.com - Investing.com Australia
Citizens reiterates Opus Genetics stock rating on gene therapy data - Investing.com
Citizens Initiates Coverage on Opus Genetics with Outperform Rating - HarianBasis.co
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Opus Genetics (IRD), NeoGenomics (NEO) and Teladoc (TDOC) - The Globe and Mail
Citizens Initiates Coverage of Opus Genetics (IRD) - Insider Monkey
IRD Stock Price, Quote & Chart | OPUS GENETICS INC (NASDAQ:IRD) - ChartMill
B. Riley Securities Maintains Opus Genetics(IRD.US) With Buy Rating, Raises Target Price to $10 - Moomoo
B. Riley Adjusts Opus Genetics Price Target to $10 From $9, Maintains Buy Rating - marketscreener.com
Opus Genetics to Participate in Leading Medical Conferences in May 2026 - Sahm
IRD Initiated Coverage by Citizens -- Rating Set to Market Outpe - GuruFocus
Opus Genetics higher after $25M private placement - MSN
Citizens JMP Initiates Opus Genetics(IRD.US) With Buy Rating, Announces Target Price $12 - Moomoo
Opus Genetics (NASDAQ:IRD) Now Covered by Analysts at Citizens Jmp - MarketBeat
Citizens initiates Opus Genetics stock coverage with outperform rating - Investing.com UK
Citizens initiates Opus Genetics stock coverage with outperform rating By Investing.com - Investing.com Australia
Citizens Initiates Coverage of Opus Genetics (IRD) with Market Outperform Recommendation - MSN
Opus Genetics (NASDAQ:IRD) CFO Robert Gagnon Sells 7,842 Shares - MarketBeat
Opus Genetics (NASDAQ:IRD) CEO Sells $49,647.42 in Stock - MarketBeat
Opus Genetics president Benjamin Yerxa sells $39,121 in stock By Investing.com - Investing.com Australia
Opus Genetics president Benjamin Yerxa sells $39,121 in stock - Investing.com
Opus Genetics CEO George Magrath sells $49,647 in stock By Investing.com - Investing.com Australia
[Form 4] Opus Genetics, Inc. Insider Trading Activity - Stock Titan
Opus Genetics CSO Jayagopal Ashwath sells $39,155 in stock By Investing.com - Investing.com South Africa
Opus Genetics CEO George Magrath sells $49,647 in stock - Investing.com UK
Opus Genetics CSO Jayagopal Ashwath sells $39,155 in stock - Investing.com
Opus Genetics (IRD) COO sells shares to cover tax withholding - Stock Titan
Small Opus Genetics (IRD) insider sale made to cover RSU taxes - Stock Titan
Opus Genetics (IRD) CEO sells 9,511 shares to cover tax withholding - Stock Titan
Opus Genetics (IRD) officer auto-sells 7,542 shares for RSU taxes - Stock Titan
Opus Genetics (IRD) CFO has 7,842 shares sold to cover RSU taxes - Stock Titan
Opus Genetics (IRD) price target increased by 23.44% to 9.73 - MSN
Opus Genetics secures up to $155M financing from Oberland Capital - MSN
Opus Genetics, Inc. Files Form 8-K: Company Information, Address, and NASDAQ Listing Details - Minichart
Opus Genetics issues $35 million in senior secured notes under new agreement By Investing.com - Investing.com South Africa
Opus Genetics issues $35 million in senior secured notes under new agreement - Investing.com UK
Finanzdaten der Opus Genetics Inc-Aktie (IRD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):